The mode of action of the antitumour agent GP 48,989 in the rat.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002369:Castration; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009368:Neoplasm Transplantation; D010053:Ovary / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D011960:Receptors, Estrogen / Q000187:drug effects; D013629:Tamoxifen / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous; D014599:Uterus / Q000473:pathology
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D013844:Thiazoles; D013629:Tamoxifen; D007986:Luteinizing Hormone